Granisetron
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Granisetron: From Antiemetic Use to Manic Bipolar Affective Disorder
One-Sentence Summary
Granisetron is a selective 5-HT3 receptor antagonist known for antiemetic use (chemotherapy/radiotherapy-induced and postoperative nausea and vomiting). The TxGNN model predicts it may be effective for manic bipolar affective disorder, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure model-generated hypothesis with no corroborating evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Antiemetic use (CINV/PONV) — based on known pharmacology of 5-HT3 antagonists; not confirmed via evidence pack (no Finland license text on file) |
| Predicted New Indication | Manic bipolar affective disorder |
| TxGNN Prediction Score | 99.62% |
| Evidence Level | L5 |
| Finland Market Status | 未上市 (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, granisetron is a selective 5-HT3 (serotonin) receptor antagonist, its efficacy in antiemetic use has been proven, and mechanistically it may theoretically extend to conditions involving serotonergic dysregulation.
The repurposing rationale supplied for this candidate notes that 5-HT3 receptor signaling has an indirect, theoretical relationship to mood regulation — pointing to small exploratory studies of the same-class drug ondansetron as adjunctive therapy in mania. However, this is explicitly flagged as speculative: there is no direct mechanistic or clinical evidence that granisetron itself has any effect on manic bipolar affective disorder.
Given the absence of clinical trials, registry entries, or literature connecting granisetron to this indication, the TxGNN score should be interpreted as a knowledge-graph-derived hypothesis rather than an evidence-backed signal. It is reasonable as a research lead worth monitoring, but not as a basis for clinical action at this time.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Finland Market Information
Granisetron is currently not marketed in Finland (0 authorizations on file); no product-level licensing data is available to tabulate.
Safety Considerations
Please refer to the package insert for safety information.
Note: TFDA package insert warnings/contraindications (DG001) are flagged as a Blocking data gap — this must be resolved before any S1 safety pre-assessment can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests solely on a TxGNN model score (L5) with no clinical trials, registry entries, or literature support, and the proposed mechanistic link between 5-HT3 antagonism and bipolar mania is speculative and drug-class-inferred rather than granisetron-specific.
To proceed, the following is needed:
- Confirmed mechanism of action data (MOA) for granisetron (DG002)
- TFDA/Fimea package insert warnings and contraindications (DG001, Blocking)
- Exploratory or preclinical studies directly evaluating 5-HT3 antagonism in bipolar/manic states
- Confirmation of original approved indication and licensing status, since Finland currently shows no marketed product
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.